We are live on ! Find out more
PIM

Partner Investment Management Portfolio holdings

AUM $13.9M Turnover 66.25%
1-Year Est. Return 55.92%
This Fund
S&P 500
This Quarter Est. Return
+4.81%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$86.8M
AUM Growth
-$18.6M
Cap. Flow
-$3.59M
Cap. Flow %
-4.13%
Top 10 Hldgs %
34.84%
Holding
103
New
20
Increased
22
Reduced
25
Closed
29
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
ALNA
Allena Pharmaceuticals
ALNA
+$7.09M
2
BIDU icon
Baidu
BIDU
+$2.46M
3
ZBH icon
Zimmer Biomet
ZBH
+$1.67M
4
CME icon
CME Group
CME
+$1.46M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.44M

Top Sells

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$2.37M
2
JD icon
JD.com
JD
+$1.84M
3
ELV icon
Elevance Health
ELV
+$1.77M
4
AGN.PRA
Allergan plc
AGN.PRA
+$1.76M
5
CNC icon
Centene
CNC
+$1.61M

Sector Composition

Rank Sector Weight
1 Healthcare 60.42%
2 Technology 16.05%
3 Miscellaneous 9.04%
4 Communication Services 6.34%
5 Financials 3.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SNNA
1
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$5.07M 5.84%
300,911
-29
-0% -$613
2017 Q3
1 quarter
ALNA
2
DELISTED
Allena Pharmaceuticals
ALNA
$4.72M 5.44%
+575,407
New +$7.09M
2017 Q4
0 quarters
PTLA
3
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$4.14M 4.77%
85,117
+3,548
+4% +$179K
2016 Q4
4 quarters
PBYI icon
4
Puma Biotechnology
PBYI
$527M
$2.61M 3%
26,369
+5,075
+24% +$568K
2016 Q4
4 quarters
GDDY icon
5
GoDaddy
GDDY
$13.1B
$2.54M 2.92%
50,419
-7,672
-13% -$364K
2016 Q4
4 quarters
BIDU icon
6
Baidu
BIDU
$27.9B
$2.35M 2.71%
+10,053
New +$2.46M
2017 Q4
0 quarters
CRM icon
7
Salesforce
CRM
$194B
$2.18M 2.51%
21,339
-936
-4% -$95.4K
2017 Q2
2 quarters
EW icon
8
Edwards Lifesciences
EW
$49.8B
$2.14M 2.46%
56,880
-12,387
-18% -$455K
2014 Q4
12 quarters
ABT icon
9
Abbott
ABT
$178B
$2.1M 2.42%
36,766
-3,122
-8% -$173K
2017 Q2
2 quarters
AERI
10
DELISTED
Aerie Pharmaceuticals
AERI
$2.01M 2.32%
33,688
+1,986
+6% +$120K
2015 Q1
11 quarters
NOW icon
11
ServiceNow
NOW
$145B
$1.78M 2.05%
68,320
+6,870
+11% +$171K
2017 Q2
2 quarters
BAX icon
12
Baxter International
BAX
$12.8B
$1.75M 2.01%
27,047
-9,336
-26% -$600K
2017 Q1
3 quarters
UNH icon
13
UnitedHealth
UNH
$355B
$1.74M 2.01%
7,908
+1,147
+17% +$243K
2016 Q2
6 quarters
ZBH icon
14
Zimmer Biomet
ZBH
$17.5B
$1.73M 1.99%
+14,767
New +$1.67M
2017 Q4
0 quarters
BABA icon
15
Alibaba
BABA
$277B
$1.61M 1.85%
9,328
+855
+10% +$153K
2017 Q1
3 quarters
DVA icon
16
DaVita
DVA
$11.5B
$1.59M 1.83%
+22,021
New +$1.36M
2017 Q4
0 quarters
BOX icon
17
Box
BOX
$5.22B
$1.56M 1.8%
74,119
+6,541
+10% +$138K
2017 Q2
2 quarters
HUM icon
18
Humana
HUM
$51.3B
$1.55M 1.79%
6,252
+1,791
+40% +$442K
2016 Q3
5 quarters
MOH icon
19
Molina Healthcare
MOH
$10.9B
$1.54M 1.78%
20,105
+5,908
+42% +$426K
2016 Q2
6 quarters
QQQ icon
20
PUT
Invesco QQQ Trust
QQQ
$488B
$1.54M 1.78%
9,900
-46,700
-83% -$7.13M
2017 Q2
2 quarters
CME icon
21
CME Group
CME
$103B
$1.49M 1.72%
+10,230
New +$1.46M
2017 Q4
0 quarters
XBI icon
22
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$1.39M 1.6%
+16,400
New +$1.37M
2017 Q4
0 quarters
HCA icon
23
HCA Healthcare
HCA
$102B
$1.36M 1.57%
+15,535
New +$1.25M
2017 Q4
0 quarters
REGN icon
24
Regeneron Pharmaceuticals
REGN
$80.1B
$1.34M 1.54%
+3,555
New +$1.44M
2017 Q4
0 quarters
PYPL icon
25
PayPal
PYPL
$48B
$1.33M 1.53%
18,019
+413
+2% +$29.9K
2016 Q4
4 quarters
1
2 3 4

Similar funds

SWM
Sequoia Wealth Management Hoffman Estates, Illinois $12.9M AUM 25.75% 1-Year Est. Return
ACM
ADI Capital Management New York $17.5M AUM 49.32% 1-Year Est. Return
ECAU
Everett Capital Advisors (UK) London, United Kingdom $18.6M AUM 22.81% 1-Year Est. Return
SL
Signition LP New York $20M AUM 28.26% 1-Year Est. Return
DII
Domini Impact Investments New York $7.59M AUM 47.68% 1-Year Est. Return
FIM
FourPoints Investment Managers Paris, France $21.1M AUM 11.11% 1-Year Est. Return
EM
Emancipation Management New York $22.4M AUM 18.33% 1-Year Est. Return
BHC
Balch Hill Capital San Francisco, California $22.8M AUM

Partner Investment Management's Q4 2017 Portfolio in Review

As of Q4 2017, Partner Investment Management held 103 positions worth $86.8M, down 18% from $105M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Partner Investment Management withdrew a net $3.59M in Q4 2017, closing 29 positions and reducing 25 holdings. Its most notable exit was Meta Platforms (Facebook), an estimated $2.37M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 43% a quarter earlier, followed by Technology and Miscellaneous.

Against the trend, Partner Investment Management opened a new position in Allena Pharmaceuticals worth $4.72M.

  • Partner Investment Management's largest Q4 2017 buy was Allena Pharmaceuticals: 575,407 shares worth $4.72M.
  • Partner Investment Management added most to Puma Biotechnology in Q4 2017, an estimated $568K increase.
  • Partner Investment Management's biggest Q4 2017 reduction was Elevance Health, cutting an estimated $1.77M.
  • Partner Investment Management fully exited Meta Platforms (Facebook) in Q4 2017, selling an estimated $2.37M.
  • Partner Investment Management's ten largest holdings make up 35% of its $86.8M portfolio in Q4 2017.
  • Partner Investment Management opened 20 new positions and closed 29 in Q4 2017.
  • Partner Investment Management's portfolio value fell 18% quarter-over-quarter to $86.8M.

Based on Partner Investment Management's 13F filing for Q4 2017, filed 14 Feb 2018.